Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Bioorg Med Chem Lett ; 23(13): 3927-34, 2013 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-23692872

RESUMEN

A novel series of α4ß2 nAChR agonists lacking common pyridine or its bioisosteric heterocycle have been disclosed. Essential pharmacophoric elements of the series are exocyclic carbonyl moiety as a hydrogen bond acceptor and secondary amino group within diaza- or azabicyclic scaffold. Computer modeling studies suggested that molecular shape of the ligand also contributes to promotion of agonism. Proof of concept for improving working memory performance in a novel object recognition task has been demonstrated on a representative of the series, 3-propionyl-3,7-diazabicyclo[3.3.0]octane (34).


Asunto(s)
Piridinas/farmacología , Receptores Nicotínicos/metabolismo , Humanos , Enlace de Hidrógeno , Modelos Moleculares , Estructura Molecular , Piridinas/síntesis química , Piridinas/química
2.
J Med Chem ; 55(21): 9181-94, 2012 Nov 08.
Artículo en Inglés | MEDLINE | ID: mdl-22793665

RESUMEN

Diversification of essential nicotinic cholinergic pharmacophoric elements, i.e., cationic center and hydrogen bond acceptor, resulted in the discovery of novel potent α4ß2 nAChR selective agonists comprising a series of N-acyldiazabicycles. Core characteristics of the series are an exocyclic carbonyl moiety as a hydrogen bond acceptor and endocyclic secondary amino group. These features are positioned at optimal distance and with optimal relative spatial orientation to provide near optimal interactions with the receptor. A novel potent and highly selective α4ß2 nAChR agonist 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (56, TC-6683, AZD1446) with favorable pharmaceutical properties and in vivo efficacy in animal models has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions and is currently being progressed to phase 2 clinical trials as a treatment for Alzheimer's disease.


Asunto(s)
Compuestos Bicíclicos Heterocíclicos con Puentes/síntesis química , Trastornos del Conocimiento/tratamiento farmacológico , Agonistas Nicotínicos/síntesis química , Receptores Nicotínicos/metabolismo , Animales , Encéfalo/metabolismo , Compuestos Bicíclicos Heterocíclicos con Puentes/química , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Línea Celular , Cricetinae , Cricetulus , Conducta Exploratoria/efectos de los fármacos , Humanos , Masculino , Modelos Moleculares , Agonistas Nicotínicos/química , Agonistas Nicotínicos/farmacología , Ratas , Ratas Sprague-Dawley , Estereoisomerismo , Relación Estructura-Actividad
3.
Org Lett ; 10(23): 5353-6, 2008 Dec 04.
Artículo en Inglés | MEDLINE | ID: mdl-19007172

RESUMEN

The first total synthesis of the natural product 3-hydroxy-11-norcytisine (1), structurally related to cytisine (2), a benchmark ligand at neuronal nicotinic acetylcholine receptors (NNRs), has been achieved. The synthesis permits the unambiguous confirmation of the structure originally proposed for 1 and has enabled initial biological characterization of 1 and its related compounds against NNRs.


Asunto(s)
Alcaloides/síntesis química , Alcaloides/metabolismo , Alcaloides/química , Animales , Azocinas/síntesis química , Azocinas/química , Azocinas/metabolismo , Espectroscopía de Resonancia Magnética , Quinolizinas/síntesis química , Quinolizinas/química , Quinolizinas/metabolismo , Ratas , Receptores Nicotínicos/metabolismo , Receptor Nicotínico de Acetilcolina alfa 7
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA